Key result
This review discusses current pharmacologic and surgical therapeutic options, including vasodilator therapy, for the management of severe pulmonary hypertension.
This review outlines the therapeutic options, including pharmacologic and surgical therapies, for managing severe pulmonary hypertension.
Summarizes current options for severe PH; leaves open optimal sequencing and comparative effectiveness trials.
Pulmonary hypertension occurs as a consequence of numerous and varied conditions, all of which result in an elevation of pulmonary vascular resistance. Over the past decade, significant progress has been made in understanding the factors which contribute to the progressive nature of pulmonary vascular disease, and in identifying new treatments for pulmonary hypertension. The majority of these therapeutic options are pharmacologic, but for specific circumstances, surgical therapy may be a consideration. This article discusses nonspecific therapies for all patients with pulmonary hypertension, vasodilator therapy (including screening for vasodilator responsiveness, standard oral agents, and newer intravenous or inhalational therapies) and surgical options applicable to specific situations.
No takes yet. Share an insight, caveat, or question.
H.I. Palevsky (1997) conducted a review in Severe pulmonary hypertension. Therapeutic options (pharmacologic and surgical) was evaluated. This review discusses current pharmacologic and surgical therapeutic options, including vasodilator therapy, for the management of severe pulmonary hypertension.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: